Arvinas Pharmaceuticals likely to reach 25.60
Arvinas Pharmaceuticals is on a run thanks to FDA approval of phase 1 clinical trials on a new drug. It's above critical resistance levels and appears to have clearance up to 25.60.
Personally I won't be taking a position in this one, though. Arvinas's earnings are pretty garbage, and honestly a phase 1 clinical trial doesn't mean much in this industry.
We've also got a Democratic debate coming up, so I've exited all my positions in pharmaceuticals and healthcare lest they take a hit due to rhetoric about universal healthcare or drug price controls. There's lots of litigation around the ACA right now that provides additional risk. I'm not sure how this fight will play out or how markets would react to the various outcomes.
Personally I won't be taking a position in this one, though. Arvinas's earnings are pretty garbage, and honestly a phase 1 clinical trial doesn't mean much in this industry.
We've also got a Democratic debate coming up, so I've exited all my positions in pharmaceuticals and healthcare lest they take a hit due to rhetoric about universal healthcare or drug price controls. There's lots of litigation around the ACA right now that provides additional risk. I'm not sure how this fight will play out or how markets would react to the various outcomes.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.